NewsAI-assisted

Evotec Secures $2.9 Million Gates Foundation Grant to Extend Stem Cell-Based Fetal Safety Screening

Evotec receives a $2.9M Gates Foundation grant to extend its hiPSC-based fetal safety screening platform for global health drug programs.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 16, 2026Updated Nov 17, 2026 · 2 min read
Evotec Secures $2.9 Million Gates Foundation Grant to Extend Stem Cell-Based Fetal Safety Screening
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
90/ 100
Trust score
High confidence

Preclinical safety assessment for global health drug programs is shifting earlier in the discovery cycle, and Evotec SE has secured a $2.9 million, three-year grant from the Gates Foundation to sustain that shift. The funding extends a 2023 collaboration focused on identifying fetal developmental risks in novel drug candidates before those compounds reach clinical testing.

The platform at the centre of this work combines human induced pluripotent stem cell (hiPSC) models with industrial-scale, high-throughput screening to generate human-relevant developmental toxicity data. Over the initial three-year project, more than 5,000 compounds were screened across nine grantee programs, a throughput figure that signals the platform's operational readiness for multi-program deployment, not just proof-of-concept work.

For preclinical and regulatory affairs teams, the relevance sits in the translational gap that animal models have historically struggled to close. Evotec's hiPSC-based teratogenicity platform generates in vitro data using human cell-derived models, supported by automation and high-content imaging, positioning it as a New Approach Methodology (NAM) with potential to inform regulatory submissions where species-specific extrapolation has been a documented limitation. The platform's development and validation methodology is currently available as a bioRxiv preprint, which regulatory leads tracking evolving NAM guidance will want to review ahead of any submission strategy discussions.

Evotec's broader NAM portfolio spans more than 25 hiPSC-derived cellular models, three-dimensional organoid systems, and AI-supported disease modeling, infrastructure that the company positions as applicable to both efficacy and safety data generation across organ systems. The Gates Foundation's continued investment reflects an external validation of the platform's data quality, though peer-reviewed publication of the full validation dataset remains a step the field will watch for.

The three-year extension runs through approximately 2029, with continued access provided to researchers working on global health programs, a population of users whose compound libraries and development timelines will stress-test the platform's scalability claims against real-world discovery workflows.

Source: Evotec SE via evotec.com, 16 November 2026.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →